BAM
APGE

Bellevue Asset Management’s Apogee Therapeutics APGE Stock Holding History

Bellevue Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24
Closed -$1.81K – 379
2025
Q4 		$1.81K Sell
24
-12
-33% -$756 ﹤0.01% 450
2025
Q3 		$1.43K Hold
36
– – ﹤0.01% 470
2025
Q2 		$1.56K Hold
36
– – ﹤0.01% 451
2025
Q1 		$1.34K Hold
36
– – ﹤0.01% 453
2024
Q4 		$1.63K Hold
36
– – ﹤0.01% 460
2024
Q3 		$2.11K Hold
36
– – ﹤0.01% 410
2024
Q2 		$1.42K Hold
36
– – ﹤0.01% 441
2024
Q1 		$2.39K Buy
+36
New +$1.57K ﹤0.01% 391

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bellevue Asset Management's APGE Position: Q1 2026 in Review

Bellevue Asset Management sold out of Apogee Therapeutics (APGE) in Q1 2026, closing a stake of 24 shares — an estimated $1.81K sold.

Bellevue Asset Management first reported a position in APGE in Q1 2024 and held it in 8 quarters. The position peaked at $2.39K in Q1 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Bellevue Asset Management reported no remaining Apogee Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bellevue Asset Management sold 24 Apogee Therapeutics shares in Q1 2026, an estimated $1.81K.
  • Bellevue Asset Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 8 quarters.
  • Bellevue Asset Management's Apogee Therapeutics position peaked at $2.39K in Q1 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.